Azithromycin dihydrate

Molecular Formula: C38H72N2O12

Molecular Weight: 749.0 g/mol

Systematic Name: (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-Ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-{[3,4,6-trideoxy-3-(dimethylamino)-D-xylo-hexopyranosyl]oxy}-1-oxa-6-azacyclopentadecan-13-yl 2,6-dideoxy-3-C-methyl-3-O-methyl-L-ribo-hexopyranoside

Trade Name(s): Zithromax, Azithrocin

Appearance: white crystalline powder

TAPI's process development and production capabilities in synthetic organic chemistry cover a broad range of synthetic products and state-of-the-art technologies.

Our development expertise is backed by our comprehensive understanding of these processes and an unwavering commitment to R&D investment. As a result, we provide you with high-quality APIs at competitive prices, while meeting the most stringent industry standards.

Our capabilities in the field of synthetic organic chemistry include, among others: O-alkylation, N-alkylation, aliphatic and aromatic nucleophilic substitution, catalytic hydrogenation, catalytic reduction, biocatalysis, and oxidation (including asymmetric sulfoxidation). TAPI provides a robust synthetic process from API conception all the way to commercial production. This process is specifically designed to be atom-efficient, safe and environmentally friendly without compromising product purity.

The most rigid analytical and physical control methods are utilized to deliver desired polymorphs compatible with the stringent demands of regulatory bodies in target countries. And, our knowledgeable IP experts are available to answer questions and help you maintain your competitive edge in the marketplace. TAPI operates seven R&D centers worldwide.

There, our top researchers with wide-ranging scientific expertise continually strive to improve our processes so you benefit from industry-leading learnings and materials. Scientists in several of TAPI's large pilot plants - with capacities ranging from 200 ml to 480 l - are developing technologies to deliver and implement new processes that will enhance our production capabilities.

Azithromycin, a semi-synthetic antibiotic, belongs to a class of drugs know as 'macrolide antibiotics,' of which all members are chemically derived from naturally occurring erythromycin. The drug is effective against numerous types of bacteria such as Hemophilus influenzae, Streptococcus pneumoniae, and S. aureus, among others. Azithromycin, like all macrolide antibiotics, prevents bacteria from growing by disrupting their ability to synthesize proteins. Due to differences in the mechanisms of protein synthesis in bacteria and humans, macrolide antibiotics do not interfere with protein production in humans. It is an unusual antibiotic in that it has a long half-life (68 h), permitting once-a-day dosing and shorter treatment times for many infections.

Presently, azithromycin is manufactured through semi-synthetic methods. Semi-synthesis is a type of a chemical synthesis that makes use of compounds isolated from natural sources (bacterial; cell cultures; plant material) as starting material. Erythromycin, a metabolic product of the actinomycete bacterium Saccharopolyspora erythraea, is the starting material for its preparation.